Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells
- 152 Downloads
Beta-irradiation used for systemic radioimmunotherapy (RIT) is a promising treatment approach for high-risk leukaemia and lymphoma. In bone marrow-selective radioimmunotherapy, beta-irradiation is applied using iodine-131, yttrium-90 or rhenium-188 labelled radioimmunoconjugates. However, the mechanisms by which beta-irradiation induces cell death are not understood at the molecular level. Here, we report that beta-irradiation induced apoptosis and activated apoptosis pathways in leukaemia cells depending on doses, time points and dose rates. After beta-irradiation, upregulation of CD95 ligand and CD95 receptor was detected and activation of caspases resulting in apoptosis was found. These effects were completely blocked by the broad-range caspase inhibitor zVAD-fmk. In addition, irradiation-mediated mitochondrial damage resulted in perturbation of mitochondrial membrane potential, caspase-9 activation and cytochrome c release. Bax, a death-promoting protein, was upregulated and Bcl-xL, a death-inhibiting protein, was downregulated. We also found higher apoptosis rates and earlier activation of apoptosis pathways after gamma-irradiation in comparison to beta-irradiation at the same dose rate. Furthermore, irradiation-resistant cells were cross-resistant to CD95 and CD95-resistant cells were cross-resistant to irradiation, indicating that CD95 and irradiation used, at least in part, identical effector pathways. These findings demonstrate that beta-irradiation induces apoptosis and activates apoptosis pathways in leukaemia cells using both mitochondrial and death receptor pathways. Understanding the timing, sequence and molecular pathways of beta-irradiation-mediated apoptosis may allow rational adjustment of chemo- and radiotherapeutic strategies.
KeywordsRadioimmunotherapy Beta-irradiation Apoptosis Leukaemia Rhenium-188
We thank Stefanie Rath for excellent technical assistance, Gerhard Glatting for help in dosimetry and Detlev Bartkowiak for providing the gamma-irradiation source.
This work was supported by BMBF IZKF C14 grant and Wilhelm Sander-Stiftung grant 2002.045.1.
- 2.Bunjes D, Buchmann I, Duncker, C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Doehner H, Bergmann, L, Reske SN. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98:565–572.PubMedGoogle Scholar
- 5.Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, Martin PJ, Mitchell D, Press OW, Storb R, Bernstein ID. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94:1237–1247.PubMedGoogle Scholar
- 6.Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56:2123–2129.PubMedGoogle Scholar
- 17.Peter M E, Kischkel FC, Hellbrandt S, Chinnaiyan AM, Krammer PH, Dixit VM. CD95 (APO-1/Fas)-associating signaling proteins. Cell Death Differ 1996; 3:161–170.Google Scholar
- 18.Debatin KM. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differ 1996; 3:185–189.Google Scholar
- 21.Fulda S, Meyer E, Friesen C, Susin SA, Kroemer E, Debatin KM. Cell type specific involvement of death receptor and mitchondrial pathways in drug-induced apoptosis. Oncogene 2001; 20:1063–1075.Google Scholar
- 23.Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 1997; 57:3331–3334.PubMedGoogle Scholar
- 28.Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397:441–446.PubMedGoogle Scholar
- 39.Carbonari M, Cibati M, Cherchi M, Sbarigia D, Pesce AM, Dell'Ann L, Modica A, Fiorelli M. Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus-infection and cancer chemotherapy by a novel flow immunocytometric method. Blood 1994; 83:1268–1277.PubMedGoogle Scholar
- 40.Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P. Topoisomerase I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and Bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta lapachone. Int J Cancer 1997; 73:707–714.CrossRefPubMedGoogle Scholar
- 42.Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399:483–487.Google Scholar